Susie Kim, MD
Cardiovascular Disease · Durango, CONPI 1548258379
Payments from drug & device makers
Across 166 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$481
- Boston Scientific$443
- Pfizer$391
- Abbott$372
- Novartis$231
- AstraZeneca$192
- plus $1K from 24 others
What the payments were for
- Travel & lodging$522%
- Food & beverage$3,29498%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 35 | $481 |
| Boston Scientific | 12 | $443 |
| Pfizer | 24 | $391 |
| Abbott | 16 | $372 |
| Novartis | 10 | $231 |
| AstraZeneca | 6 | $192 |
| E.r. Squibb & Sons, L.L.C. | 10 | $186 |
| Boehringer Ingelheim | 3 | $153 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $131 |
| Merck | 7 | $101 |
| Heartflow, Inc. | 4 | $85 |
| Abiomed | 2 | $63 |
| Cardiovascular Systems Inc. | 1 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Medtronic(2 entities) | 2 | $46 |
| Johnson & Johnson | 3 | $44 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $35 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Philips North America LLC | 1 | $34 |
| Chiesi USA, Inc. | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 2 | $32 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Impulse Dynamics (USA) Inc. | 1 | $20 |
| Angiodynamics, Inc. | 1 | $20 |
| Biotronik Inc. | 1 | $17 |
| Inari Medical, Inc. | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$122
- GENERAL - THERAPIES$121
- FARXIGA$111
How this compares
$3,375 in reported general payments places this provider in the 55th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 139 | $148,609 |
| Repatha SureclickEvolocumab | 73 | $54,259 |
| XareltoRivaroxaban | 33 | $33,764 |
| FarxigaDapagliflozin Propanediol | 26 | $22,477 |
| EntrestoSacubitril/Valsartan | 12 | $20,128 |
| JardianceEmpagliflozin | 14 | $18,514 |
| Metoprolol Succinate | 147 | $1,383 |
| Rosuvastatin Calcium | 93 | $1,196 |
| Atorvastatin Calcium | 153 | $1,184 |
| Losartan Potassium | 94 | $775 |
| Nebivolol Hcl | 15 | $685 |
| Spironolactone | 92 | $575 |
| Amlodipine Besylate | 76 | $501 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 25 | $490 |
| Valsartan | 23 | $438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $391 | $148,609139 claims |
| Johnson & JohnsonXarelto | $44 | $33,76433 claims |
| AstraZenecaFarxiga | $192 | $22,47726 claims |
| NovartisEntresto | $231 | $20,12812 claims |
| Boehringer IngelheimJardiance | $153 | $18,51414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Durango
- William AndersonDurango$187K
- Gary LuckasenFort Collins$11M
- Payal KohliAurora$1.7M
- Marc BonacaAurora$1.2M
- William SauerAurora$978K
- John AltmanLakewood$797K
- Nampalli VijayDenver$711K
- Brack HattlerAurora$699K
- Lin-Wang DongGreeley$640K
- Jake ChaninDenver$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.